Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ACTRIMS 2021 | The perpetual multi-center multi-regimen Healy-ALS Platform trial

Robert Glanzman, MD, FAAN, Clene Nanomedicine Inc, Salt Lake City, UT, discusses the HEALEY ALS Platform Trial (NCT04297683), a multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational amyotrophic lateral sclerosis (ALS) therapies. HEALEY ALS is the first platform trial to be conducted in ALS and by testing numerous therapies simultaneously, it will cut trial time, costs and increase patient participation. CNM-Au8, a pure gold nanocrystal-based therapy in a new class of novel nanocatalytic drugs, is under Phase III investigation as part of this program. Enrolment is ongoing. This interview took place during the ACTRIMS Forum 2021.


Dr Glanzman is an employee of Clene Nanomedicine.